# Meriva curcumin-phospholipid complex, 2 g/day, as add-on therapy × Improvement of PASI in mild-to-moderate plaque psoriasis Verdict 3042 · Evidence Check Stored-material review date: Not recorded Original evidence cut-off: 2026-09-08 Review-criteria version: 1.0 Public page/material preparation date: 2026-10-24 Clinical papers were not read directly; existing review summaries were checked. No new clinical-literature search was performed. Unverified does not mean that research is absent or that there is no effect. ## Assessment scope - Population: The retained population is adults with mild-to-moderate plaque psoriasis and PASI below 10. Diagnosis, baseline characteristics, history, prior treatments and exclusion criteria remain incompletely verified; scope is not extended to other severities or psoriasis types. - Ingredient, formulation and route: The record describes a commercial Meriva phospholipid phytosome containing Curcuma longa curcuminoids in a soy-lecithin carrier, with approximately 20% curcuminoids. Batches, measured amounts and bioavailability remain unverified; equivalence to other curcumin formulations is not established. - Dose: The original value is 2 g/day of the Meriva product. It is not equated to 2 g of conventional curcumin or converted into an active-ingredient amount. Actual dosing, adherence, changes and exposure remain unverified. - Comparator: The comparison is Meriva added to topical steroids common to both groups versus topical steroids alone. The record states that there was no oral add-on placebo; topical-agent ingredients, potency, use, changes and rescue treatment remain incompletely verified. - Measured outcome: The selected endpoint is PASI change at 12 weeks. Exact between-group adjusted estimates, 95% CIs, prespecified hierarchy, measurement and denominators remain unverified. Secondary PASI75, the mechanistic IL-22 marker and quality of life address separate questions. - Duration: The record describes 12 weeks of treatment and follow-up. Visit schedules, actual exposure, post-treatment persistence, relapse and long-term follow-up remain unverified; scope is not extended to long-term efficacy or safety. - Questions outside this scope: The original C/50/Caution and B/S/R1/I0/E+/B2/C0 are retained. Historical cross-checking and positive-result narratives are historical records, not current external original-source reading, reassessment or independent clinical certification.; 63 assigned participants, 49 completers and the original narrative of 22% attrition are retained separately as original values. Group analysis denominators, ITT and missing-data handling remain unverified; completer results are not relabeled as analyses of all assigned participants, and attrition is not recalculated.; The qualitative record describes decreases in both groups, with a larger decrease in the Meriva add-on arm. Exact between-group differences, adjustment models, 95% CIs and P values remain unverified; no new difference or interval is generated.; Reported randomization/double blinding and a no-add-on control without an oral add-on placebo are both retained. Actual fulfillment of participant, assessor or analyst blinding is not established here.; PASI change remains distinct from secondary PASI75, the IL-22 mechanism and quality of life. Secondary/mechanistic signals do not substitute for the selected PASI question's prespecified hierarchy, exact add-on effect or patient importance.; The original record of Indena support and product-related interests is retained. Original funding, product provision, employee authorship, individual COI and research/publication roles remain unread; involvement routes are not newly established or relabeled as absence of support.; Original precautions that 12 weeks cannot exclude long-term hepatic, biliary or bleeding risks, and that soy-lecithin allergy depends on product composition, are retained. Actual events, collection, exposure/denominators, causality, allergy populations and long-term safety remain unverified.; The original evidence date 2026-09-08, correction of 1 English field on 2026-09-14 and stored-material production date 2026-10-06 remain distinct. Actual content-review dates remain unrecorded; PMID, PMCID and bibliographic links are not relabeled as current original-paper reading. ## Checklist items ### N01 · Which PASI add-on effect is presented? Verification status: Partly verified Reading scope: The retained Korean and English summaries and bibliography were read. External papers, abstracts/full texts, registration, protocols, analysis plans, result tables and support disclosures remain unread, with no access attempt. - Current findings: The original claim concerns PASI improvement in mild-to-moderate plaque psoriasis. Scope is the add-on effect of a specific phospholipid complex alongside topical steroids. - Why unverified: Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified. - Reason for missing information: Meriva monotherapy and effects of other formulations are outside this selected question. - Required materials and conditions: 12-week PASI with Meriva plus topical steroids versus common topical steroids alone - Materials to obtain first: Original-trial intervention, comparator and endpoint specifications - Further research: Material needed: Original-trial intervention, comparator and endpoint specifications. This records needed materials; no new research was executed. - Conditions for verification: Original records on 12-week PASI with Meriva plus topical steroids versus common topical steroids alone must link to populations, products, common treatment, between-group add-on effects, denominators, PASI analyses and timepoints, distinguishing stored information from what remains unverified. - Why this condition is needed: Material on 12-week PASI with Meriva plus topical steroids versus common topical steroids alone is needed to connect the relevant psoriasis population, Meriva formulation, add-on/common treatment, PASI measurement/timepoint, allocation/completion/analysis denominator or harm scope. - Application exceptions: Effects of a specific formulation added to common topical steroids remain distinct from monotherapy or replacement treatment. Completer results are not relabeled as analyses of all assigned participants; active amounts or new attrition rates are not calculated from product amounts or original records. Scope is not extended to other formulations, secondary endpoints, mechanisms or long-term safety. - Remaining uncertainty: Gaps remain in diagnosis, products, actual exposure, topical treatment, placebo/blinding, measurement, add-on effects/intervals, denominators, attrition/missingness, support and harms. Original numbers, grades and historical verification wording do not constitute new calculation, reassessment or clinical validation. - Referenced methods: Existing principles distinguish population, commercial formulation, product amount/duration, common topical treatment, no-add-on control, measurement, allocation/completion/analysis denominators, support and harms in the retained Meriva PASI record. - Related sources: S01 ### N02 · Which psoriasis population is included? Verification status: Partly verified Reading scope: The retained Korean and English summaries and bibliography were read. External papers, abstracts/full texts, registration, protocols, analysis plans, result tables and support disclosures remain unread, with no access attempt. - Current findings: The retained scope describes adults with mild-to-moderate plaque psoriasis and PASI below 10. - Why unverified: Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified. - Reason for missing information: Diagnostic methods, history, baseline characteristics, prior treatments and exclusion criteria remain incompletely verified. - Required materials and conditions: Eligibility of adults with mild-to-moderate plaque psoriasis and PASI below 10 - Materials to obtain first: Diagnosis, eligibility and baseline-characteristic tables - Further research: Material needed: Diagnosis, eligibility and baseline-characteristic tables. This records needed materials; no new research was executed. - Conditions for verification: Original records on Eligibility of adults with mild-to-moderate plaque psoriasis and PASI below 10 must link to populations, products, common treatment, between-group add-on effects, denominators, PASI analyses and timepoints, distinguishing stored information from what remains unverified. - Why this condition is needed: Material on Eligibility of adults with mild-to-moderate plaque psoriasis and PASI below 10 is needed to connect the relevant psoriasis population, Meriva formulation, add-on/common treatment, PASI measurement/timepoint, allocation/completion/analysis denominator or harm scope. - Application exceptions: Effects of a specific formulation added to common topical steroids remain distinct from monotherapy or replacement treatment. Completer results are not relabeled as analyses of all assigned participants; active amounts or new attrition rates are not calculated from product amounts or original records. Scope is not extended to other formulations, secondary endpoints, mechanisms or long-term safety. - Remaining uncertainty: Gaps remain in diagnosis, products, actual exposure, topical treatment, placebo/blinding, measurement, add-on effects/intervals, denominators, attrition/missingness, support and harms. Original numbers, grades and historical verification wording do not constitute new calculation, reassessment or clinical validation. - Referenced methods: Existing principles distinguish population, commercial formulation, product amount/duration, common topical treatment, no-add-on control, measurement, allocation/completion/analysis denominators, support and harms in the retained Meriva PASI record. - Related sources: S01 ### N03 · What are the Meriva carrier and quantified composition? Verification status: Partly verified Reading scope: The retained Korean and English summaries and bibliography were read. External papers, abstracts/full texts, registration, protocols, analysis plans, result tables and support disclosures remain unread, with no access attempt. - Current findings: The retained formulation is a commercial phospholipid phytosome with approximately 20% curcuminoids, using a soy-lecithin carrier. - Why unverified: Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified. - Reason for missing information: Product batches, measured composition, manufacturing and bioavailability material remain unverified. Ingredient amounts are not newly converted. - Required materials and conditions: Commercial phospholipid phytosome, approximately 20% curcuminoids and soy lecithin - Materials to obtain first: Product, batch and ingredient-quantification specifications - Further research: Material needed: Product, batch and ingredient-quantification specifications. This records needed materials; no new research was executed. - Conditions for verification: Original records on Commercial phospholipid phytosome, approximately 20% curcuminoids and soy lecithin must link to populations, products, common treatment, between-group add-on effects, denominators, PASI analyses and timepoints, distinguishing stored information from what remains unverified. - Why this condition is needed: Material on Commercial phospholipid phytosome, approximately 20% curcuminoids and soy lecithin is needed to connect the relevant psoriasis population, Meriva formulation, add-on/common treatment, PASI measurement/timepoint, allocation/completion/analysis denominator or harm scope. - Application exceptions: Effects of a specific formulation added to common topical steroids remain distinct from monotherapy or replacement treatment. Completer results are not relabeled as analyses of all assigned participants; active amounts or new attrition rates are not calculated from product amounts or original records. Scope is not extended to other formulations, secondary endpoints, mechanisms or long-term safety. - Remaining uncertainty: Gaps remain in diagnosis, products, actual exposure, topical treatment, placebo/blinding, measurement, add-on effects/intervals, denominators, attrition/missingness, support and harms. Original numbers, grades and historical verification wording do not constitute new calculation, reassessment or clinical validation. - Referenced methods: Existing principles distinguish population, commercial formulation, product amount/duration, common topical treatment, no-add-on control, measurement, allocation/completion/analysis denominators, support and harms in the retained Meriva PASI record. - Related sources: S01 ### N04 · Is oral Meriva interchangeable with other curcumin products? Verification status: Partly verified Reading scope: The retained Korean and English summaries and bibliography were read. External papers, abstracts/full texts, registration, protocols, analysis plans, result tables and support disclosures remain unread, with no access attempt. - Current findings: The selected intervention is oral Meriva. The original record limits interchangeability across other formulations and routes. - Why unverified: Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified. - Reason for missing information: Identical effects across other products and routes remain unverified. - Required materials and conditions: Distinguishing oral phospholipid complexes from conventional powder, nano, micellar, piperine-combination and topical products - Materials to obtain first: Direct comparisons for each product and route - Further research: Material needed: Direct comparisons for each product and route. This records needed materials; no new research was executed. - Conditions for verification: Original records on Distinguishing oral phospholipid complexes from conventional powder, nano, micellar, piperine-combination and topical products must link to populations, products, common treatment, between-group add-on effects, denominators, PASI analyses and timepoints, distinguishing stored information from what remains unverified. - Why this condition is needed: Material on Distinguishing oral phospholipid complexes from conventional powder, nano, micellar, piperine-combination and topical products is needed to connect the relevant psoriasis population, Meriva formulation, add-on/common treatment, PASI measurement/timepoint, allocation/completion/analysis denominator or harm scope. - Application exceptions: Effects of a specific formulation added to common topical steroids remain distinct from monotherapy or replacement treatment. Completer results are not relabeled as analyses of all assigned participants; active amounts or new attrition rates are not calculated from product amounts or original records. Scope is not extended to other formulations, secondary endpoints, mechanisms or long-term safety. - Remaining uncertainty: Gaps remain in diagnosis, products, actual exposure, topical treatment, placebo/blinding, measurement, add-on effects/intervals, denominators, attrition/missingness, support and harms. Original numbers, grades and historical verification wording do not constitute new calculation, reassessment or clinical validation. - Referenced methods: Existing principles distinguish population, commercial formulation, product amount/duration, common topical treatment, no-add-on control, measurement, allocation/completion/analysis denominators, support and harms in the retained Meriva PASI record. - Related sources: S01 ### N05 · What does 2 g/day represent? Verification status: Partly verified Reading scope: The retained Korean and English summaries and bibliography were read. External papers, abstracts/full texts, registration, protocols, analysis plans, result tables and support disclosures remain unread, with no access attempt. - Current findings: The retained dose is 2 g/day of Meriva. It is not equated to 2 g of conventional curcumin. - Why unverified: Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified. - Reason for missing information: Actual dosing, adherence, active-ingredient exposure and dose changes remain unverified. - Required materials and conditions: 2 g/day of the Meriva product, with actual dosing and adherence - Materials to obtain first: Product amounts, dosing adherence and change records - Further research: Material needed: Product amounts, dosing adherence and change records. This records needed materials; no new research was executed. - Conditions for verification: Original records on 2 g/day of the Meriva product, with actual dosing and adherence must link to populations, products, common treatment, between-group add-on effects, denominators, PASI analyses and timepoints, distinguishing stored information from what remains unverified. - Why this condition is needed: Material on 2 g/day of the Meriva product, with actual dosing and adherence is needed to connect the relevant psoriasis population, Meriva formulation, add-on/common treatment, PASI measurement/timepoint, allocation/completion/analysis denominator or harm scope. - Application exceptions: Effects of a specific formulation added to common topical steroids remain distinct from monotherapy or replacement treatment. Completer results are not relabeled as analyses of all assigned participants; active amounts or new attrition rates are not calculated from product amounts or original records. Scope is not extended to other formulations, secondary endpoints, mechanisms or long-term safety. - Remaining uncertainty: Gaps remain in diagnosis, products, actual exposure, topical treatment, placebo/blinding, measurement, add-on effects/intervals, denominators, attrition/missingness, support and harms. Original numbers, grades and historical verification wording do not constitute new calculation, reassessment or clinical validation. - Referenced methods: Existing principles distinguish population, commercial formulation, product amount/duration, common topical treatment, no-add-on control, measurement, allocation/completion/analysis denominators, support and harms in the retained Meriva PASI record. - Related sources: S01 ### N06 · Does benefit persist beyond 12 weeks? Verification status: Unverified Reading scope: The retained Korean and English summaries and bibliography were read. External papers, abstracts/full texts, registration, protocols, analysis plans, result tables and support disclosures remain unread, with no access attempt. - Current findings: The retained duration is 12 weeks of treatment and follow-up, with long-term relapse described as unknown. - Why unverified: Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified. - Reason for missing information: Post-treatment persistence, relapse and long-term follow-up remain unverified. - Required materials and conditions: 12 weeks of treatment/follow-up and subsequent persistence/relapse - Materials to obtain first: Visit schedules and post-treatment follow-up - Further research: Material needed: Visit schedules and post-treatment follow-up. This records needed materials; no new research was executed. - Conditions for verification: Original records on 12 weeks of treatment/follow-up and subsequent persistence/relapse must link to populations, products, common treatment, between-group add-on effects, denominators, PASI analyses and timepoints, distinguishing stored information from what remains unverified. - Why this condition is needed: Material on 12 weeks of treatment/follow-up and subsequent persistence/relapse is needed to connect the relevant psoriasis population, Meriva formulation, add-on/common treatment, PASI measurement/timepoint, allocation/completion/analysis denominator or harm scope. - Application exceptions: Effects of a specific formulation added to common topical steroids remain distinct from monotherapy or replacement treatment. Completer results are not relabeled as analyses of all assigned participants; active amounts or new attrition rates are not calculated from product amounts or original records. Scope is not extended to other formulations, secondary endpoints, mechanisms or long-term safety. - Remaining uncertainty: Gaps remain in diagnosis, products, actual exposure, topical treatment, placebo/blinding, measurement, add-on effects/intervals, denominators, attrition/missingness, support and harms. Original numbers, grades and historical verification wording do not constitute new calculation, reassessment or clinical validation. - Referenced methods: Existing principles distinguish population, commercial formulation, product amount/duration, common topical treatment, no-add-on control, measurement, allocation/completion/analysis denominators, support and harms in the retained Meriva PASI record. - Related sources: S01 ### N07 · How was common topical-steroid treatment aligned? Verification status: Partly verified Reading scope: The retained Korean and English summaries and bibliography were read. External papers, abstracts/full texts, registration, protocols, analysis plans, result tables and support disclosures remain unread, with no access attempt. - Current findings: The record states that both groups used topical steroids and differed by added Meriva. - Why unverified: Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified. - Reason for missing information: Topical ingredients, potency, dose, application sites, amounts, changes and rescue treatment remain incompletely verified. - Required materials and conditions: Topical-steroid ingredients, potency, sites, use and changes in both groups - Materials to obtain first: Topical-steroid and rescue-treatment records - Further research: Material needed: Topical-steroid and rescue-treatment records. This records needed materials; no new research was executed. - Conditions for verification: Original records on Topical-steroid ingredients, potency, sites, use and changes in both groups must link to populations, products, common treatment, between-group add-on effects, denominators, PASI analyses and timepoints, distinguishing stored information from what remains unverified. - Why this condition is needed: Material on Topical-steroid ingredients, potency, sites, use and changes in both groups is needed to connect the relevant psoriasis population, Meriva formulation, add-on/common treatment, PASI measurement/timepoint, allocation/completion/analysis denominator or harm scope. - Application exceptions: Effects of a specific formulation added to common topical steroids remain distinct from monotherapy or replacement treatment. Completer results are not relabeled as analyses of all assigned participants; active amounts or new attrition rates are not calculated from product amounts or original records. Scope is not extended to other formulations, secondary endpoints, mechanisms or long-term safety. - Remaining uncertainty: Gaps remain in diagnosis, products, actual exposure, topical treatment, placebo/blinding, measurement, add-on effects/intervals, denominators, attrition/missingness, support and harms. Original numbers, grades and historical verification wording do not constitute new calculation, reassessment or clinical validation. - Referenced methods: Existing principles distinguish population, commercial formulation, product amount/duration, common topical treatment, no-add-on control, measurement, allocation/completion/analysis denominators, support and harms in the retained Meriva PASI record. - Related sources: S01 ### N08 · Did the control group receive an oral placebo? Verification status: Partly verified Reading scope: The retained Korean and English summaries and bibliography were read. External papers, abstracts/full texts, registration, protocols, analysis plans, result tables and support disclosures remain unread, with no access attempt. - Current findings: The original record describes a comparison against topical steroids alone without placebo. The retained evidence also describes a no-add-on control. - Why unverified: Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified. - Reason for missing information: Detailed control of expectancy, adherence and concurrent-management differences remains unverified. - Required materials and conditions: Distinguishing no-add-on controls from add-on-placebo controls - Materials to obtain first: Control-intervention, visit and management specifications - Further research: Material needed: Control-intervention, visit and management specifications. This records needed materials; no new research was executed. - Conditions for verification: Original records on Distinguishing no-add-on controls from add-on-placebo controls must link to populations, products, common treatment, between-group add-on effects, denominators, PASI analyses and timepoints, distinguishing stored information from what remains unverified. - Why this condition is needed: Material on Distinguishing no-add-on controls from add-on-placebo controls is needed to connect the relevant psoriasis population, Meriva formulation, add-on/common treatment, PASI measurement/timepoint, allocation/completion/analysis denominator or harm scope. - Application exceptions: Effects of a specific formulation added to common topical steroids remain distinct from monotherapy or replacement treatment. Completer results are not relabeled as analyses of all assigned participants; active amounts or new attrition rates are not calculated from product amounts or original records. Scope is not extended to other formulations, secondary endpoints, mechanisms or long-term safety. - Remaining uncertainty: Gaps remain in diagnosis, products, actual exposure, topical treatment, placebo/blinding, measurement, add-on effects/intervals, denominators, attrition/missingness, support and harms. Original numbers, grades and historical verification wording do not constitute new calculation, reassessment or clinical validation. - Referenced methods: Existing principles distinguish population, commercial formulation, product amount/duration, common topical treatment, no-add-on control, measurement, allocation/completion/analysis denominators, support and harms in the retained Meriva PASI record. - Related sources: S01 ### N09 · What is the identity of the direct report? Verification status: Partly verified Reading scope: The retained Korean and English summaries and bibliography were read. External papers, abstracts/full texts, registration, protocols, analysis plans, result tables and support disclosures remain unread, with no access attempt. - Current findings: The stored bibliography records Antiga 2015, PMID 26090395, PMCID PMC4450233, DOI 10.1155/2015/283634. - Why unverified: Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified. - Reason for missing information: Current external bibliographic/original-file identity and full text remain unread. - Required materials and conditions: Retained links among the Antiga report title, PMID, PMCID and DOI - Materials to obtain first: Original paper and bibliographic records - Further research: Material needed: Original paper and bibliographic records. This records needed materials; no new research was executed. - Conditions for verification: Original records on Retained links among the Antiga report title, PMID, PMCID and DOI must link to populations, products, common treatment, between-group add-on effects, denominators, PASI analyses and timepoints, distinguishing stored information from what remains unverified. - Why this condition is needed: Material on Retained links among the Antiga report title, PMID, PMCID and DOI is needed to connect the relevant psoriasis population, Meriva formulation, add-on/common treatment, PASI measurement/timepoint, allocation/completion/analysis denominator or harm scope. - Application exceptions: Effects of a specific formulation added to common topical steroids remain distinct from monotherapy or replacement treatment. Completer results are not relabeled as analyses of all assigned participants; active amounts or new attrition rates are not calculated from product amounts or original records. Scope is not extended to other formulations, secondary endpoints, mechanisms or long-term safety. - Remaining uncertainty: Gaps remain in diagnosis, products, actual exposure, topical treatment, placebo/blinding, measurement, add-on effects/intervals, denominators, attrition/missingness, support and harms. Original numbers, grades and historical verification wording do not constitute new calculation, reassessment or clinical validation. - Referenced methods: Existing principles distinguish population, commercial formulation, product amount/duration, common topical treatment, no-add-on control, measurement, allocation/completion/analysis denominators, support and harms in the retained Meriva PASI record. - Related sources: S01 ### N10 · Were registration and a prespecified study plan provided? Verification status: Unverified Reading scope: The retained Korean and English summaries and bibliography were read. External papers, abstracts/full texts, registration, protocols, analysis plans, result tables and support disclosures remain unread, with no access attempt. - Current findings: The retained trial-registration field remains unverified, and the citation contains no registration identifier. - Why unverified: Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified. - Reason for missing information: Original registration, prespecification timing, protocol and amendment history remain unread. - Required materials and conditions: Registration identifiers/timing, protocol and amendments - Materials to obtain first: Original registration, protocol and amendments - Further research: Material needed: Original registration, protocol and amendments. This records needed materials; no new research was executed. - Conditions for verification: Original records on Registration identifiers/timing, protocol and amendments must link to populations, products, common treatment, between-group add-on effects, denominators, PASI analyses and timepoints, distinguishing stored information from what remains unverified. - Why this condition is needed: Material on Registration identifiers/timing, protocol and amendments is needed to connect the relevant psoriasis population, Meriva formulation, add-on/common treatment, PASI measurement/timepoint, allocation/completion/analysis denominator or harm scope. - Application exceptions: Effects of a specific formulation added to common topical steroids remain distinct from monotherapy or replacement treatment. Completer results are not relabeled as analyses of all assigned participants; active amounts or new attrition rates are not calculated from product amounts or original records. Scope is not extended to other formulations, secondary endpoints, mechanisms or long-term safety. - Remaining uncertainty: Gaps remain in diagnosis, products, actual exposure, topical treatment, placebo/blinding, measurement, add-on effects/intervals, denominators, attrition/missingness, support and harms. Original numbers, grades and historical verification wording do not constitute new calculation, reassessment or clinical validation. - Referenced methods: Existing principles distinguish population, commercial formulation, product amount/duration, common topical treatment, no-add-on control, measurement, allocation/completion/analysis denominators, support and harms in the retained Meriva PASI record. - Related sources: S01 ### N11 · What is the hierarchy of PASI change and PASI75? Verification status: Partly verified Reading scope: The retained Korean and English summaries and bibliography were read. External papers, abstracts/full texts, registration, protocols, analysis plans, result tables and support disclosures remain unread, with no access attempt. - Current findings: The retained endpoint is PASI change at 12 weeks, with PASI75 described as secondary. - Why unverified: Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified. - Reason for missing information: The exact prespecified primary (1st) hierarchy, multiple endpoints and timepoint plans remain unverified. - Required materials and conditions: Distinguishing 12-week PASI change from secondary PASI75 results - Materials to obtain first: Endpoint hierarchy in registration, protocol and SAP - Further research: Material needed: Endpoint hierarchy in registration, protocol and SAP. This records needed materials; no new research was executed. - Conditions for verification: Original records on Distinguishing 12-week PASI change from secondary PASI75 results must link to populations, products, common treatment, between-group add-on effects, denominators, PASI analyses and timepoints, distinguishing stored information from what remains unverified. - Why this condition is needed: Material on Distinguishing 12-week PASI change from secondary PASI75 results is needed to connect the relevant psoriasis population, Meriva formulation, add-on/common treatment, PASI measurement/timepoint, allocation/completion/analysis denominator or harm scope. - Application exceptions: Effects of a specific formulation added to common topical steroids remain distinct from monotherapy or replacement treatment. Completer results are not relabeled as analyses of all assigned participants; active amounts or new attrition rates are not calculated from product amounts or original records. Scope is not extended to other formulations, secondary endpoints, mechanisms or long-term safety. - Remaining uncertainty: Gaps remain in diagnosis, products, actual exposure, topical treatment, placebo/blinding, measurement, add-on effects/intervals, denominators, attrition/missingness, support and harms. Original numbers, grades and historical verification wording do not constitute new calculation, reassessment or clinical validation. - Referenced methods: Existing principles distinguish population, commercial formulation, product amount/duration, common topical treatment, no-add-on control, measurement, allocation/completion/analysis denominators, support and harms in the retained Meriva PASI record. - Related sources: S01 ### N12 · What were the allocation and concealment methods? Verification status: Partly verified Reading scope: The retained Korean and English summaries and bibliography were read. External papers, abstracts/full texts, registration, protocols, analysis plans, result tables and support disclosures remain unread, with no access attempt. - Current findings: The report is retained as a randomized add-on trial. - Why unverified: Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified. - Reason for missing information: Details of allocation sequence, concealment procedures and recruitment flow remain unverified. - Required materials and conditions: Randomization procedures, allocation concealment and participant flow - Materials to obtain first: Allocation methods and participant-flow diagrams - Further research: Material needed: Allocation methods and participant-flow diagrams. This records needed materials; no new research was executed. - Conditions for verification: Original records on Randomization procedures, allocation concealment and participant flow must link to populations, products, common treatment, between-group add-on effects, denominators, PASI analyses and timepoints, distinguishing stored information from what remains unverified. - Why this condition is needed: Material on Randomization procedures, allocation concealment and participant flow is needed to connect the relevant psoriasis population, Meriva formulation, add-on/common treatment, PASI measurement/timepoint, allocation/completion/analysis denominator or harm scope. - Application exceptions: Effects of a specific formulation added to common topical steroids remain distinct from monotherapy or replacement treatment. Completer results are not relabeled as analyses of all assigned participants; active amounts or new attrition rates are not calculated from product amounts or original records. Scope is not extended to other formulations, secondary endpoints, mechanisms or long-term safety. - Remaining uncertainty: Gaps remain in diagnosis, products, actual exposure, topical treatment, placebo/blinding, measurement, add-on effects/intervals, denominators, attrition/missingness, support and harms. Original numbers, grades and historical verification wording do not constitute new calculation, reassessment or clinical validation. - Referenced methods: Existing principles distinguish population, commercial formulation, product amount/duration, common topical treatment, no-add-on control, measurement, allocation/completion/analysis denominators, support and harms in the retained Meriva PASI record. - Related sources: S01 ### N13 · How are reported double blinding and the no-add-on control interpreted? Verification status: Unverified Reading scope: The retained Korean and English summaries and bibliography were read. External papers, abstracts/full texts, registration, protocols, analysis plans, result tables and support disclosures remain unread, with no access attempt. - Current findings: The retained evidence describes a trial reported as double-blind, with a no-add-on control. Reported wording does not establish actual fulfillment of blinding. - Why unverified: Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified. - Reason for missing information: Participant-, assessor- and analyst-specific blinding methods and maintenance remain unverified. - Required materials and conditions: Blinded parties, maintenance/unblinding and actual control interventions - Materials to obtain first: Original blinding-party, placebo and assessment procedures - Further research: Material needed: Original blinding-party, placebo and assessment procedures. This records needed materials; no new research was executed. - Conditions for verification: Original records on Blinded parties, maintenance/unblinding and actual control interventions must link to populations, products, common treatment, between-group add-on effects, denominators, PASI analyses and timepoints, distinguishing stored information from what remains unverified. - Why this condition is needed: Material on Blinded parties, maintenance/unblinding and actual control interventions is needed to connect the relevant psoriasis population, Meriva formulation, add-on/common treatment, PASI measurement/timepoint, allocation/completion/analysis denominator or harm scope. - Application exceptions: Effects of a specific formulation added to common topical steroids remain distinct from monotherapy or replacement treatment. Completer results are not relabeled as analyses of all assigned participants; active amounts or new attrition rates are not calculated from product amounts or original records. Scope is not extended to other formulations, secondary endpoints, mechanisms or long-term safety. - Remaining uncertainty: Gaps remain in diagnosis, products, actual exposure, topical treatment, placebo/blinding, measurement, add-on effects/intervals, denominators, attrition/missingness, support and harms. Original numbers, grades and historical verification wording do not constitute new calculation, reassessment or clinical validation. - Referenced methods: Existing principles distinguish population, commercial formulation, product amount/duration, common topical treatment, no-add-on control, measurement, allocation/completion/analysis denominators, support and harms in the retained Meriva PASI record. - Related sources: S01 ### N14 · What denominators do 63 assigned and 49 completed represent? Verification status: Partly verified Reading scope: The retained Korean and English summaries and bibliography were read. External papers, abstracts/full texts, registration, protocols, analysis plans, result tables and support disclosures remain unread, with no access attempt. - Current findings: The retained sample description is 63 assigned participants and 49 completers. Completer results are not relabeled as analyses of all assigned participants. - Why unverified: Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified. - Reason for missing information: Group-specific allocation, completion and analysis counts, and ITT denominators, remain unverified. - Required materials and conditions: Distinguishing allocated, completed and endpoint-specific analysis denominators - Materials to obtain first: Group flow, analysis populations and result tables - Further research: Material needed: Group flow, analysis populations and result tables. This records needed materials; no new research was executed. - Conditions for verification: Original records on Distinguishing allocated, completed and endpoint-specific analysis denominators must link to populations, products, common treatment, between-group add-on effects, denominators, PASI analyses and timepoints, distinguishing stored information from what remains unverified. - Why this condition is needed: Material on Distinguishing allocated, completed and endpoint-specific analysis denominators is needed to connect the relevant psoriasis population, Meriva formulation, add-on/common treatment, PASI measurement/timepoint, allocation/completion/analysis denominator or harm scope. - Application exceptions: Effects of a specific formulation added to common topical steroids remain distinct from monotherapy or replacement treatment. Completer results are not relabeled as analyses of all assigned participants; active amounts or new attrition rates are not calculated from product amounts or original records. Scope is not extended to other formulations, secondary endpoints, mechanisms or long-term safety. - Remaining uncertainty: Gaps remain in diagnosis, products, actual exposure, topical treatment, placebo/blinding, measurement, add-on effects/intervals, denominators, attrition/missingness, support and harms. Original numbers, grades and historical verification wording do not constitute new calculation, reassessment or clinical validation. - Referenced methods: Existing principles distinguish population, commercial formulation, product amount/duration, common topical treatment, no-add-on control, measurement, allocation/completion/analysis denominators, support and harms in the retained Meriva PASI record. - Related sources: S01 ### N15 · What does the original 22% attrition describe? Verification status: Unverified Reading scope: The retained Korean and English summaries and bibliography were read. External papers, abstracts/full texts, registration, protocols, analysis plans, result tables and support disclosures remain unread, with no access attempt. - Current findings: The original record describes 22% attrition. This historical value is retained without recalculation. - Why unverified: Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified. - Reason for missing information: Attrition timing, reasons, group distribution and associations with outcomes remain unverified. - Required materials and conditions: Attrition reasons, distribution by group and the recorded 22% - Materials to obtain first: Attrition/discontinuation reasons and group flow - Further research: Material needed: Attrition/discontinuation reasons and group flow. This records needed materials; no new research was executed. - Conditions for verification: Original records on Attrition reasons, distribution by group and the recorded 22% must link to populations, products, common treatment, between-group add-on effects, denominators, PASI analyses and timepoints, distinguishing stored information from what remains unverified. - Why this condition is needed: Material on Attrition reasons, distribution by group and the recorded 22% is needed to connect the relevant psoriasis population, Meriva formulation, add-on/common treatment, PASI measurement/timepoint, allocation/completion/analysis denominator or harm scope. - Application exceptions: Effects of a specific formulation added to common topical steroids remain distinct from monotherapy or replacement treatment. Completer results are not relabeled as analyses of all assigned participants; active amounts or new attrition rates are not calculated from product amounts or original records. Scope is not extended to other formulations, secondary endpoints, mechanisms or long-term safety. - Remaining uncertainty: Gaps remain in diagnosis, products, actual exposure, topical treatment, placebo/blinding, measurement, add-on effects/intervals, denominators, attrition/missingness, support and harms. Original numbers, grades and historical verification wording do not constitute new calculation, reassessment or clinical validation. - Referenced methods: Existing principles distinguish population, commercial formulation, product amount/duration, common topical treatment, no-add-on control, measurement, allocation/completion/analysis denominators, support and harms in the retained Meriva PASI record. - Related sources: S01 ### N16 · What are the completer analysis and missing-data assumptions? Verification status: Unverified Reading scope: The retained Korean and English summaries and bibliography were read. External papers, abstracts/full texts, registration, protocols, analysis plans, result tables and support disclosures remain unread, with no access attempt. - Current findings: The original record describes positive PASI results among 49 completers. - Why unverified: Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified. - Reason for missing information: ITT status, missing-data handling, adjustment models and sensitivity analyses remain unverified. - Required materials and conditions: Results in 49 completers, ITT, missing-data handling and analysis models - Materials to obtain first: SAP, analysis populations and missing-data material - Further research: Material needed: SAP, analysis populations and missing-data material. This records needed materials; no new research was executed. - Conditions for verification: Original records on Results in 49 completers, ITT, missing-data handling and analysis models must link to populations, products, common treatment, between-group add-on effects, denominators, PASI analyses and timepoints, distinguishing stored information from what remains unverified. - Why this condition is needed: Material on Results in 49 completers, ITT, missing-data handling and analysis models is needed to connect the relevant psoriasis population, Meriva formulation, add-on/common treatment, PASI measurement/timepoint, allocation/completion/analysis denominator or harm scope. - Application exceptions: Effects of a specific formulation added to common topical steroids remain distinct from monotherapy or replacement treatment. Completer results are not relabeled as analyses of all assigned participants; active amounts or new attrition rates are not calculated from product amounts or original records. Scope is not extended to other formulations, secondary endpoints, mechanisms or long-term safety. - Remaining uncertainty: Gaps remain in diagnosis, products, actual exposure, topical treatment, placebo/blinding, measurement, add-on effects/intervals, denominators, attrition/missingness, support and harms. Original numbers, grades and historical verification wording do not constitute new calculation, reassessment or clinical validation. - Referenced methods: Existing principles distinguish population, commercial formulation, product amount/duration, common topical treatment, no-add-on control, measurement, allocation/completion/analysis denominators, support and harms in the retained Meriva PASI record. - Related sources: S01 ### N17 · How was PASI measured? Verification status: Partly verified Reading scope: The retained Korean and English summaries and bibliography were read. External papers, abstracts/full texts, registration, protocols, analysis plans, result tables and support disclosures remain unread, with no access attempt. - Current findings: The selected endpoint is PASI change at 12 weeks. - Why unverified: Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified. - Reason for missing information: PASI measurement procedures, assessor reliability, baseline values and group distributions remain unverified. - Required materials and conditions: PASI scoring, baseline values, assessors and 12-week measurement - Materials to obtain first: Scale, baseline values, assessment procedures and result tables - Further research: Material needed: Scale, baseline values, assessment procedures and result tables. This records needed materials; no new research was executed. - Conditions for verification: Original records on PASI scoring, baseline values, assessors and 12-week measurement must link to populations, products, common treatment, between-group add-on effects, denominators, PASI analyses and timepoints, distinguishing stored information from what remains unverified. - Why this condition is needed: Material on PASI scoring, baseline values, assessors and 12-week measurement is needed to connect the relevant psoriasis population, Meriva formulation, add-on/common treatment, PASI measurement/timepoint, allocation/completion/analysis denominator or harm scope. - Application exceptions: Effects of a specific formulation added to common topical steroids remain distinct from monotherapy or replacement treatment. Completer results are not relabeled as analyses of all assigned participants; active amounts or new attrition rates are not calculated from product amounts or original records. Scope is not extended to other formulations, secondary endpoints, mechanisms or long-term safety. - Remaining uncertainty: Gaps remain in diagnosis, products, actual exposure, topical treatment, placebo/blinding, measurement, add-on effects/intervals, denominators, attrition/missingness, support and harms. Original numbers, grades and historical verification wording do not constitute new calculation, reassessment or clinical validation. - Referenced methods: Existing principles distinguish population, commercial formulation, product amount/duration, common topical treatment, no-add-on control, measurement, allocation/completion/analysis denominators, support and harms in the retained Meriva PASI record. - Related sources: S01 ### N18 · What underlies decreases in both groups and the larger add-on decrease? Verification status: Partly verified Reading scope: The retained Korean and English summaries and bibliography were read. External papers, abstracts/full texts, registration, protocols, analysis plans, result tables and support disclosures remain unread, with no access attempt. - Current findings: The stored result is a narrative of decreases in both groups, with a larger decrease in the Meriva add-on arm. - Why unverified: Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified. - Reason for missing information: Exact group changes, between-group estimates and adjustment models are absent from the current summary. A new difference is not generated. - Required materials and conditions: Group PASI changes and the exact between-group add-on effect - Materials to obtain first: Original group tables, between-group effects and analysis output - Further research: Material needed: Original group tables, between-group effects and analysis output. This records needed materials; no new research was executed. - Conditions for verification: Original records on Group PASI changes and the exact between-group add-on effect must link to populations, products, common treatment, between-group add-on effects, denominators, PASI analyses and timepoints, distinguishing stored information from what remains unverified. - Why this condition is needed: Material on Group PASI changes and the exact between-group add-on effect is needed to connect the relevant psoriasis population, Meriva formulation, add-on/common treatment, PASI measurement/timepoint, allocation/completion/analysis denominator or harm scope. - Application exceptions: Effects of a specific formulation added to common topical steroids remain distinct from monotherapy or replacement treatment. Completer results are not relabeled as analyses of all assigned participants; active amounts or new attrition rates are not calculated from product amounts or original records. Scope is not extended to other formulations, secondary endpoints, mechanisms or long-term safety. - Remaining uncertainty: Gaps remain in diagnosis, products, actual exposure, topical treatment, placebo/blinding, measurement, add-on effects/intervals, denominators, attrition/missingness, support and harms. Original numbers, grades and historical verification wording do not constitute new calculation, reassessment or clinical validation. - Referenced methods: Existing principles distinguish population, commercial formulation, product amount/duration, common topical treatment, no-add-on control, measurement, allocation/completion/analysis denominators, support and harms in the retained Meriva PASI record. - Related sources: S01 ### N19 · Is an exact adjusted-effect interval available? Verification status: Unverified Reading scope: The retained Korean and English summaries and bibliography were read. External papers, abstracts/full texts, registration, protocols, analysis plans, result tables and support disclosures remain unread, with no access attempt. - Current findings: The stored result leaves the exact adjusted CI unverified. - Why unverified: Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified. - Reason for missing information: Adjusted estimates, 95% CIs and model details are absent. Denominators alone do not establish precision. - Required materials and conditions: Between-group adjusted PASI estimate and 95% CI - Materials to obtain first: Between-group adjusted estimates, 95% CIs and models - Further research: Material needed: Between-group adjusted estimates, 95% CIs and models. This records needed materials; no new research was executed. - Conditions for verification: Original records on Between-group adjusted PASI estimate and 95% CI must link to populations, products, common treatment, between-group add-on effects, denominators, PASI analyses and timepoints, distinguishing stored information from what remains unverified. - Why this condition is needed: Material on Between-group adjusted PASI estimate and 95% CI is needed to connect the relevant psoriasis population, Meriva formulation, add-on/common treatment, PASI measurement/timepoint, allocation/completion/analysis denominator or harm scope. - Application exceptions: Effects of a specific formulation added to common topical steroids remain distinct from monotherapy or replacement treatment. Completer results are not relabeled as analyses of all assigned participants; active amounts or new attrition rates are not calculated from product amounts or original records. Scope is not extended to other formulations, secondary endpoints, mechanisms or long-term safety. - Remaining uncertainty: Gaps remain in diagnosis, products, actual exposure, topical treatment, placebo/blinding, measurement, add-on effects/intervals, denominators, attrition/missingness, support and harms. Original numbers, grades and historical verification wording do not constitute new calculation, reassessment or clinical validation. - Referenced methods: Existing principles distinguish population, commercial formulation, product amount/duration, common topical treatment, no-add-on control, measurement, allocation/completion/analysis denominators, support and harms in the retained Meriva PASI record. - Related sources: S01 ### N20 · What are the tests, multiplicity and analysis timepoints? Verification status: Unverified Reading scope: The retained Korean and English summaries and bibliography were read. External papers, abstracts/full texts, registration, protocols, analysis plans, result tables and support disclosures remain unread, with no access attempt. - Current findings: The current summary retains a directionally positive narrative. - Why unverified: Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified. - Reason for missing information: Exact P values, multiplicity adjustment, timepoint selection and reporting plans remain unverified. - Required materials and conditions: Exact PASI tests, P values, adjustment and prespecified plans - Materials to obtain first: SAP, all tests and result tables - Further research: Material needed: SAP, all tests and result tables. This records needed materials; no new research was executed. - Conditions for verification: Original records on Exact PASI tests, P values, adjustment and prespecified plans must link to populations, products, common treatment, between-group add-on effects, denominators, PASI analyses and timepoints, distinguishing stored information from what remains unverified. - Why this condition is needed: Material on Exact PASI tests, P values, adjustment and prespecified plans is needed to connect the relevant psoriasis population, Meriva formulation, add-on/common treatment, PASI measurement/timepoint, allocation/completion/analysis denominator or harm scope. - Application exceptions: Effects of a specific formulation added to common topical steroids remain distinct from monotherapy or replacement treatment. Completer results are not relabeled as analyses of all assigned participants; active amounts or new attrition rates are not calculated from product amounts or original records. Scope is not extended to other formulations, secondary endpoints, mechanisms or long-term safety. - Remaining uncertainty: Gaps remain in diagnosis, products, actual exposure, topical treatment, placebo/blinding, measurement, add-on effects/intervals, denominators, attrition/missingness, support and harms. Original numbers, grades and historical verification wording do not constitute new calculation, reassessment or clinical validation. - Referenced methods: Existing principles distinguish population, commercial formulation, product amount/duration, common topical treatment, no-add-on control, measurement, allocation/completion/analysis denominators, support and harms in the retained Meriva PASI record. - Related sources: S01 ### N21 · Is the PASI difference clinically important? Verification status: Unverified Reading scope: The retained Korean and English summaries and bibliography were read. External papers, abstracts/full texts, registration, protocols, analysis plans, result tables and support disclosures remain unread, with no access attempt. - Current findings: The retained record centers on PASI and separates quality of life. - Why unverified: Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified. - Reason for missing information: Important differences, patient-perceived changes and links to quality-of-life results remain unverified. - Required materials and conditions: Patient importance, responders and quality of life for scale changes - Materials to obtain first: Important-difference, patient-reported and quality-of-life material - Further research: Material needed: Important-difference, patient-reported and quality-of-life material. This records needed materials; no new research was executed. - Conditions for verification: Original records on Patient importance, responders and quality of life for scale changes must link to populations, products, common treatment, between-group add-on effects, denominators, PASI analyses and timepoints, distinguishing stored information from what remains unverified. - Why this condition is needed: Material on Patient importance, responders and quality of life for scale changes is needed to connect the relevant psoriasis population, Meriva formulation, add-on/common treatment, PASI measurement/timepoint, allocation/completion/analysis denominator or harm scope. - Application exceptions: Effects of a specific formulation added to common topical steroids remain distinct from monotherapy or replacement treatment. Completer results are not relabeled as analyses of all assigned participants; active amounts or new attrition rates are not calculated from product amounts or original records. Scope is not extended to other formulations, secondary endpoints, mechanisms or long-term safety. - Remaining uncertainty: Gaps remain in diagnosis, products, actual exposure, topical treatment, placebo/blinding, measurement, add-on effects/intervals, denominators, attrition/missingness, support and harms. Original numbers, grades and historical verification wording do not constitute new calculation, reassessment or clinical validation. - Referenced methods: Existing principles distinguish population, commercial formulation, product amount/duration, common topical treatment, no-add-on control, measurement, allocation/completion/analysis denominators, support and harms in the retained Meriva PASI record. - Related sources: S01 ### N22 · Does PASI75 replace the central result? Verification status: Partly verified Reading scope: The retained Korean and English summaries and bibliography were read. External papers, abstracts/full texts, registration, protocols, analysis plans, result tables and support disclosures remain unread, with no access attempt. - Current findings: PASI75 is retained as a secondary result. It does not replace prespecification or the exact effect for PASI change. - Why unverified: Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified. - Reason for missing information: Group-specific PASI75 responders, denominators, exact effects and CIs remain unverified. - Required materials and conditions: Denominators, response and intervals for secondary PASI75 - Materials to obtain first: PASI75 result tables and prespecified hierarchy - Further research: Material needed: PASI75 result tables and prespecified hierarchy. This records needed materials; no new research was executed. - Conditions for verification: Original records on Denominators, response and intervals for secondary PASI75 must link to populations, products, common treatment, between-group add-on effects, denominators, PASI analyses and timepoints, distinguishing stored information from what remains unverified. - Why this condition is needed: Material on Denominators, response and intervals for secondary PASI75 is needed to connect the relevant psoriasis population, Meriva formulation, add-on/common treatment, PASI measurement/timepoint, allocation/completion/analysis denominator or harm scope. - Application exceptions: Effects of a specific formulation added to common topical steroids remain distinct from monotherapy or replacement treatment. Completer results are not relabeled as analyses of all assigned participants; active amounts or new attrition rates are not calculated from product amounts or original records. Scope is not extended to other formulations, secondary endpoints, mechanisms or long-term safety. - Remaining uncertainty: Gaps remain in diagnosis, products, actual exposure, topical treatment, placebo/blinding, measurement, add-on effects/intervals, denominators, attrition/missingness, support and harms. Original numbers, grades and historical verification wording do not constitute new calculation, reassessment or clinical validation. - Referenced methods: Existing principles distinguish population, commercial formulation, product amount/duration, common topical treatment, no-add-on control, measurement, allocation/completion/analysis denominators, support and harms in the retained Meriva PASI record. - Related sources: S01 ### N23 · Is IL-22 direction the same outcome as the PASI effect? Verification status: Partly verified Reading scope: The retained Korean and English summaries and bibliography were read. External papers, abstracts/full texts, registration, protocols, analysis plans, result tables and support disclosures remain unread, with no access attempt. - Current findings: The original record describes concordant directions for PASI reduction and IL-22. - Why unverified: Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified. - Reason for missing information: Exact IL-22 estimates, prespecified hierarchy and relationship to the clinical scale remain unverified. - Required materials and conditions: Distinguishing the IL-22 mechanistic marker from the PASI clinical scale - Materials to obtain first: Separate mechanistic and PASI result tables - Further research: Material needed: Separate mechanistic and PASI result tables. This records needed materials; no new research was executed. - Conditions for verification: Original records on Distinguishing the IL-22 mechanistic marker from the PASI clinical scale must link to populations, products, common treatment, between-group add-on effects, denominators, PASI analyses and timepoints, distinguishing stored information from what remains unverified. - Why this condition is needed: Material on Distinguishing the IL-22 mechanistic marker from the PASI clinical scale is needed to connect the relevant psoriasis population, Meriva formulation, add-on/common treatment, PASI measurement/timepoint, allocation/completion/analysis denominator or harm scope. - Application exceptions: Effects of a specific formulation added to common topical steroids remain distinct from monotherapy or replacement treatment. Completer results are not relabeled as analyses of all assigned participants; active amounts or new attrition rates are not calculated from product amounts or original records. Scope is not extended to other formulations, secondary endpoints, mechanisms or long-term safety. - Remaining uncertainty: Gaps remain in diagnosis, products, actual exposure, topical treatment, placebo/blinding, measurement, add-on effects/intervals, denominators, attrition/missingness, support and harms. Original numbers, grades and historical verification wording do not constitute new calculation, reassessment or clinical validation. - Referenced methods: Existing principles distinguish population, commercial formulation, product amount/duration, common topical treatment, no-add-on control, measurement, allocation/completion/analysis denominators, support and harms in the retained Meriva PASI record. - Related sources: S01 ### N24 · Is there independent replication for the same formulation? Verification status: Unverified Reading scope: The retained Korean and English summaries and bibliography were read. External papers, abstracts/full texts, registration, protocols, analysis plans, result tables and support disclosures remain unread, with no access attempt. - Current findings: The retained evidence and citation describe one direct report. Multiple outcomes within one report are not counted as multiple trials. - Why unverified: Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified. - Reason for missing information: Independent replication and unique-trial/participant totals for the same product, population and add-on regimen remain unverified. - Required materials and conditions: Report-to-trial links and formulation-specific independent replication - Materials to obtain first: Replication reports and trial links under the same conditions - Further research: Material needed: Replication reports and trial links under the same conditions. This records needed materials; no new research was executed. - Conditions for verification: Original records on Report-to-trial links and formulation-specific independent replication must link to populations, products, common treatment, between-group add-on effects, denominators, PASI analyses and timepoints, distinguishing stored information from what remains unverified. - Why this condition is needed: Material on Report-to-trial links and formulation-specific independent replication is needed to connect the relevant psoriasis population, Meriva formulation, add-on/common treatment, PASI measurement/timepoint, allocation/completion/analysis denominator or harm scope. - Application exceptions: Effects of a specific formulation added to common topical steroids remain distinct from monotherapy or replacement treatment. Completer results are not relabeled as analyses of all assigned participants; active amounts or new attrition rates are not calculated from product amounts or original records. Scope is not extended to other formulations, secondary endpoints, mechanisms or long-term safety. - Remaining uncertainty: Gaps remain in diagnosis, products, actual exposure, topical treatment, placebo/blinding, measurement, add-on effects/intervals, denominators, attrition/missingness, support and harms. Original numbers, grades and historical verification wording do not constitute new calculation, reassessment or clinical validation. - Referenced methods: Existing principles distinguish population, commercial formulation, product amount/duration, common topical treatment, no-add-on control, measurement, allocation/completion/analysis denominators, support and harms in the retained Meriva PASI record. - Related sources: S01 ### N25 · What information underlies manufacturer Indena support? Verification status: Partly verified Reading scope: The retained Korean and English summaries and bibliography were read. External papers, abstracts/full texts, registration, protocols, analysis plans, result tables and support disclosures remain unread, with no access attempt. - Current findings: The retained funding description records Indena support and product-related interests. - Why unverified: Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified. - Reason for missing information: Support types/amounts and roles in design, analysis, original data and publication remain incompletely verified. - Required materials and conditions: Manufacturer funding, product support and research roles - Materials to obtain first: Original funding, product-support and manufacturer-role disclosures - Further research: Material needed: Original funding, product-support and manufacturer-role disclosures. This records needed materials; no new research was executed. - Conditions for verification: Original records on Manufacturer funding, product support and research roles must link to populations, products, common treatment, between-group add-on effects, denominators, PASI analyses and timepoints, distinguishing stored information from what remains unverified. - Why this condition is needed: Material on Manufacturer funding, product support and research roles is needed to connect the relevant psoriasis population, Meriva formulation, add-on/common treatment, PASI measurement/timepoint, allocation/completion/analysis denominator or harm scope. - Application exceptions: Effects of a specific formulation added to common topical steroids remain distinct from monotherapy or replacement treatment. Completer results are not relabeled as analyses of all assigned participants; active amounts or new attrition rates are not calculated from product amounts or original records. Scope is not extended to other formulations, secondary endpoints, mechanisms or long-term safety. - Remaining uncertainty: Gaps remain in diagnosis, products, actual exposure, topical treatment, placebo/blinding, measurement, add-on effects/intervals, denominators, attrition/missingness, support and harms. Original numbers, grades and historical verification wording do not constitute new calculation, reassessment or clinical validation. - Referenced methods: Existing principles distinguish population, commercial formulation, product amount/duration, common topical treatment, no-add-on control, measurement, allocation/completion/analysis denominators, support and harms in the retained Meriva PASI record. - Related sources: S01 ### N26 · Are product provision, employee authors and COI separately known? Verification status: Unverified Reading scope: The retained Korean and English summaries and bibliography were read. External papers, abstracts/full texts, registration, protocols, analysis plans, result tables and support disclosures remain unread, with no access attempt. - Current findings: Manufacturer-support wording is retained without establishing product provision, employee authorship or declared COI individually. - Why unverified: Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified. - Reason for missing information: Specific documents on individual product support, author affiliations/employment and COI remain unverified. - Required materials and conditions: Distinguishing product provision, author employment, COI declarations and funding - Materials to obtain first: Original product-provision, author-affiliation and COI disclosures - Further research: Material needed: Original product-provision, author-affiliation and COI disclosures. This records needed materials; no new research was executed. - Conditions for verification: Original records on Distinguishing product provision, author employment, COI declarations and funding must link to populations, products, common treatment, between-group add-on effects, denominators, PASI analyses and timepoints, distinguishing stored information from what remains unverified. - Why this condition is needed: Material on Distinguishing product provision, author employment, COI declarations and funding is needed to connect the relevant psoriasis population, Meriva formulation, add-on/common treatment, PASI measurement/timepoint, allocation/completion/analysis denominator or harm scope. - Application exceptions: Effects of a specific formulation added to common topical steroids remain distinct from monotherapy or replacement treatment. Completer results are not relabeled as analyses of all assigned participants; active amounts or new attrition rates are not calculated from product amounts or original records. Scope is not extended to other formulations, secondary endpoints, mechanisms or long-term safety. - Remaining uncertainty: Gaps remain in diagnosis, products, actual exposure, topical treatment, placebo/blinding, measurement, add-on effects/intervals, denominators, attrition/missingness, support and harms. Original numbers, grades and historical verification wording do not constitute new calculation, reassessment or clinical validation. - Referenced methods: Existing principles distinguish population, commercial formulation, product amount/duration, common topical treatment, no-add-on control, measurement, allocation/completion/analysis denominators, support and harms in the retained Meriva PASI record. - Related sources: S01 ### N27 · How were short-term adverse events in the same population collected? Verification status: Unverified Reading scope: The retained Korean and English summaries and bibliography were read. External papers, abstracts/full texts, registration, protocols, analysis plans, result tables and support disclosures remain unread, with no access attempt. - Current findings: The retained safety wording limits exclusion of long-term harms from 12-week material. - Why unverified: Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified. - Reason for missing information: Short-term adverse-event definitions, collection, group events/denominators and discontinuation reasons remain unverified. - Required materials and conditions: Event definitions, collection methods and group exposure denominators - Materials to obtain first: Adverse-event tables, collection methods and exposure denominators - Further research: Material needed: Adverse-event tables, collection methods and exposure denominators. This records needed materials; no new research was executed. - Conditions for verification: Original records on Event definitions, collection methods and group exposure denominators must link to populations, products, common treatment, between-group add-on effects, denominators, PASI analyses and timepoints, distinguishing stored information from what remains unverified. - Why this condition is needed: Material on Event definitions, collection methods and group exposure denominators is needed to connect the relevant psoriasis population, Meriva formulation, add-on/common treatment, PASI measurement/timepoint, allocation/completion/analysis denominator or harm scope. - Application exceptions: Effects of a specific formulation added to common topical steroids remain distinct from monotherapy or replacement treatment. Completer results are not relabeled as analyses of all assigned participants; active amounts or new attrition rates are not calculated from product amounts or original records. Scope is not extended to other formulations, secondary endpoints, mechanisms or long-term safety. - Remaining uncertainty: Gaps remain in diagnosis, products, actual exposure, topical treatment, placebo/blinding, measurement, add-on effects/intervals, denominators, attrition/missingness, support and harms. Original numbers, grades and historical verification wording do not constitute new calculation, reassessment or clinical validation. - Referenced methods: Existing principles distinguish population, commercial formulation, product amount/duration, common topical treatment, no-add-on control, measurement, allocation/completion/analysis denominators, support and harms in the retained Meriva PASI record. - Related sources: S01 ### N28 · Are long-term hepatic, biliary and bleeding risks answered? Verification status: Unverified Reading scope: The retained Korean and English summaries and bibliography were read. External papers, abstracts/full texts, registration, protocols, analysis plans, result tables and support disclosures remain unread, with no access attempt. - Current findings: The original record says 12-week material cannot exclude long-term hepatic, biliary or bleeding risks. - Why unverified: Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified. - Reason for missing information: Long-term follow-up, concomitant medicines, event comparisons and harm denominators remain unverified. - Required materials and conditions: Harms beyond 12 weeks, concomitant medicines and long-term follow-up - Materials to obtain first: Long-term harm, concomitant-medicine and follow-up material - Further research: Material needed: Long-term harm, concomitant-medicine and follow-up material. This records needed materials; no new research was executed. - Conditions for verification: Original records on Harms beyond 12 weeks, concomitant medicines and long-term follow-up must link to populations, products, common treatment, between-group add-on effects, denominators, PASI analyses and timepoints, distinguishing stored information from what remains unverified. - Why this condition is needed: Material on Harms beyond 12 weeks, concomitant medicines and long-term follow-up is needed to connect the relevant psoriasis population, Meriva formulation, add-on/common treatment, PASI measurement/timepoint, allocation/completion/analysis denominator or harm scope. - Application exceptions: Effects of a specific formulation added to common topical steroids remain distinct from monotherapy or replacement treatment. Completer results are not relabeled as analyses of all assigned participants; active amounts or new attrition rates are not calculated from product amounts or original records. Scope is not extended to other formulations, secondary endpoints, mechanisms or long-term safety. - Remaining uncertainty: Gaps remain in diagnosis, products, actual exposure, topical treatment, placebo/blinding, measurement, add-on effects/intervals, denominators, attrition/missingness, support and harms. Original numbers, grades and historical verification wording do not constitute new calculation, reassessment or clinical validation. - Referenced methods: Existing principles distinguish population, commercial formulation, product amount/duration, common topical treatment, no-add-on control, measurement, allocation/completion/analysis denominators, support and harms in the retained Meriva PASI record. - Related sources: S01 ### N29 · What product condition underlies soy-lecithin allergy concerns? Verification status: Unverified Reading scope: The retained Korean and English summaries and bibliography were read. External papers, abstracts/full texts, registration, protocols, analysis plans, result tables and support disclosures remain unread, with no access attempt. - Current findings: The retained record describes a soy-lecithin carrier and allergy checks depending on product composition. - Why unverified: Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified. - Reason for missing information: Trial allergy-exclusion criteria, events and exact product ingredient lists remain unverified. - Required materials and conditions: Phospholipid-carrier composition and allergy populations/events - Materials to obtain first: Product composition, allergy criteria and event material - Further research: Material needed: Product composition, allergy criteria and event material. This records needed materials; no new research was executed. - Conditions for verification: Original records on Phospholipid-carrier composition and allergy populations/events must link to populations, products, common treatment, between-group add-on effects, denominators, PASI analyses and timepoints, distinguishing stored information from what remains unverified. - Why this condition is needed: Material on Phospholipid-carrier composition and allergy populations/events is needed to connect the relevant psoriasis population, Meriva formulation, add-on/common treatment, PASI measurement/timepoint, allocation/completion/analysis denominator or harm scope. - Application exceptions: Effects of a specific formulation added to common topical steroids remain distinct from monotherapy or replacement treatment. Completer results are not relabeled as analyses of all assigned participants; active amounts or new attrition rates are not calculated from product amounts or original records. Scope is not extended to other formulations, secondary endpoints, mechanisms or long-term safety. - Remaining uncertainty: Gaps remain in diagnosis, products, actual exposure, topical treatment, placebo/blinding, measurement, add-on effects/intervals, denominators, attrition/missingness, support and harms. Original numbers, grades and historical verification wording do not constitute new calculation, reassessment or clinical validation. - Referenced methods: Existing principles distinguish population, commercial formulation, product amount/duration, common topical treatment, no-add-on control, measurement, allocation/completion/analysis denominators, support and harms in the retained Meriva PASI record. - Related sources: S01 ### N30 · Can findings extend to generic turmeric treatment or steroid replacement? Verification status: Partly verified Reading scope: The retained Korean and English summaries and bibliography were read. External papers, abstracts/full texts, registration, protocols, analysis plans, result tables and support disclosures remain unread, with no access attempt. - Current findings: The original record limits extension to treatment with dietary turmeric/generic powder or replacement of topical steroids. - Why unverified: Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified. - Reason for missing information: Direct comparisons on monotherapy effects, treatment discontinuation/replacement and other products remain unverified. - Required materials and conditions: Distinguishing add-on therapy from monotherapy and treatment replacement - Materials to obtain first: Direct monotherapy and replacement-treatment comparisons - Further research: Material needed: Direct monotherapy and replacement-treatment comparisons. This records needed materials; no new research was executed. - Conditions for verification: Original records on Distinguishing add-on therapy from monotherapy and treatment replacement must link to populations, products, common treatment, between-group add-on effects, denominators, PASI analyses and timepoints, distinguishing stored information from what remains unverified. - Why this condition is needed: Material on Distinguishing add-on therapy from monotherapy and treatment replacement is needed to connect the relevant psoriasis population, Meriva formulation, add-on/common treatment, PASI measurement/timepoint, allocation/completion/analysis denominator or harm scope. - Application exceptions: Effects of a specific formulation added to common topical steroids remain distinct from monotherapy or replacement treatment. Completer results are not relabeled as analyses of all assigned participants; active amounts or new attrition rates are not calculated from product amounts or original records. Scope is not extended to other formulations, secondary endpoints, mechanisms or long-term safety. - Remaining uncertainty: Gaps remain in diagnosis, products, actual exposure, topical treatment, placebo/blinding, measurement, add-on effects/intervals, denominators, attrition/missingness, support and harms. Original numbers, grades and historical verification wording do not constitute new calculation, reassessment or clinical validation. - Referenced methods: Existing principles distinguish population, commercial formulation, product amount/duration, common topical treatment, no-add-on control, measurement, allocation/completion/analysis denominators, support and harms in the retained Meriva PASI record. - Related sources: S01 ### N31 · How are current Korean/English records and the English correction retained? Verification status: Partly verified Reading scope: The retained Korean and English summaries and bibliography were read. External papers, abstracts/full texts, registration, protocols, analysis plans, result tables and support disclosures remain unread, with no access attempt. - Current findings: Current Korean/English material and the correction of 1 English field are retained. Generic English wording does not substitute for verification of exact numbers or denominators. - Why unverified: Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified. - Reason for missing information: Historical before/after English and full-text alignment remain incompletely verified from current inputs alone. - Required materials and conditions: Current English wording, generic evidence wording and correction of 1 field on 2026-09-14 - Materials to obtain first: Before/after-correction and language-alignment material - Further research: Material needed: Before/after-correction and language-alignment material. This records needed materials; no new research was executed. - Conditions for verification: Original records on Current English wording, generic evidence wording and correction of 1 field on 2026-09-14 must link to populations, products, common treatment, between-group add-on effects, denominators, PASI analyses and timepoints, distinguishing stored information from what remains unverified. - Why this condition is needed: Material on Current English wording, generic evidence wording and correction of 1 field on 2026-09-14 is needed to connect the relevant psoriasis population, Meriva formulation, add-on/common treatment, PASI measurement/timepoint, allocation/completion/analysis denominator or harm scope. - Application exceptions: Effects of a specific formulation added to common topical steroids remain distinct from monotherapy or replacement treatment. Completer results are not relabeled as analyses of all assigned participants; active amounts or new attrition rates are not calculated from product amounts or original records. Scope is not extended to other formulations, secondary endpoints, mechanisms or long-term safety. - Remaining uncertainty: Gaps remain in diagnosis, products, actual exposure, topical treatment, placebo/blinding, measurement, add-on effects/intervals, denominators, attrition/missingness, support and harms. Original numbers, grades and historical verification wording do not constitute new calculation, reassessment or clinical validation. - Referenced methods: Existing principles distinguish population, commercial formulation, product amount/duration, common topical treatment, no-add-on control, measurement, allocation/completion/analysis denominators, support and harms in the retained Meriva PASI record. - Related sources: S01 ### N32 · What are C/50, original axes and historical cross-checking? Verification status: Partly verified Reading scope: The retained Korean and English summaries and bibliography were read. External papers, abstracts/full texts, registration, protocols, analysis plans, result tables and support disclosures remain unread, with no access attempt. - Current findings: C/50, all axes and historical cross-checking wording are retained as historical values. They are not inherited as completed current content review or fulfilled conditions. - Why unverified: Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified. - Reason for missing information: Completed content review is not recorded in the retained material. - Required materials and conditions: Original grade, score, axes including I0, E+ and C0, and historical records - Materials to obtain first: Review comments and future correction material - Further research: Material needed: Review comments and future correction material. This records needed materials; no new research was executed. - Conditions for verification: Original records on Original grade, score, axes including I0, E+ and C0, and historical records must link to populations, products, common treatment, between-group add-on effects, denominators, PASI analyses and timepoints, distinguishing stored information from what remains unverified. - Why this condition is needed: Material on Original grade, score, axes including I0, E+ and C0, and historical records is needed to connect the relevant psoriasis population, Meriva formulation, add-on/common treatment, PASI measurement/timepoint, allocation/completion/analysis denominator or harm scope. - Application exceptions: Effects of a specific formulation added to common topical steroids remain distinct from monotherapy or replacement treatment. Completer results are not relabeled as analyses of all assigned participants; active amounts or new attrition rates are not calculated from product amounts or original records. Scope is not extended to other formulations, secondary endpoints, mechanisms or long-term safety. - Remaining uncertainty: Gaps remain in diagnosis, products, actual exposure, topical treatment, placebo/blinding, measurement, add-on effects/intervals, denominators, attrition/missingness, support and harms. Original numbers, grades and historical verification wording do not constitute new calculation, reassessment or clinical validation. - Referenced methods: Existing principles distinguish population, commercial formulation, product amount/duration, common topical treatment, no-add-on control, measurement, allocation/completion/analysis denominators, support and harms in the retained Meriva PASI record. - Related sources: S01 ### N33 · What are the original dates, blank fields and actual reading scope? Verification status: Partly verified Reading scope: The retained Korean and English summaries and bibliography were read. External papers, abstracts/full texts, registration, protocols, analysis plans, result tables and support disclosures remain unread, with no access attempt. - Current findings: The full retained record was used for preparation. Original verdict date 2026-09-08, correction date 2026-09-14 and blank original values remain preserved. - Why unverified: Information in stored summaries is linked to gaps in detailed material. External verification and content review remain incomplete; fulfilled conditions, effects, safety, prespecification and independence are not certified. - Reason for missing information: External abstracts, full texts, registration, protocols and SAPs remain unread, with no access attempt. - Required materials and conditions: Original verdict/correction dates, absence of additional selected questions, blank additional-review notes and external unread status - Materials to obtain first: Needed original material and study plans when provided - Further research: Material needed: Needed original material and study plans when provided. This records needed materials; no new research was executed. - Conditions for verification: Original records on Original verdict/correction dates, absence of additional selected questions, blank additional-review notes and external unread status must link to populations, products, common treatment, between-group add-on effects, denominators, PASI analyses and timepoints, distinguishing stored information from what remains unverified. - Why this condition is needed: Material on Original verdict/correction dates, absence of additional selected questions, blank additional-review notes and external unread status is needed to connect the relevant psoriasis population, Meriva formulation, add-on/common treatment, PASI measurement/timepoint, allocation/completion/analysis denominator or harm scope. - Application exceptions: Effects of a specific formulation added to common topical steroids remain distinct from monotherapy or replacement treatment. Completer results are not relabeled as analyses of all assigned participants; active amounts or new attrition rates are not calculated from product amounts or original records. Scope is not extended to other formulations, secondary endpoints, mechanisms or long-term safety. - Remaining uncertainty: Gaps remain in diagnosis, products, actual exposure, topical treatment, placebo/blinding, measurement, add-on effects/intervals, denominators, attrition/missingness, support and harms. Original numbers, grades and historical verification wording do not constitute new calculation, reassessment or clinical validation. - Referenced methods: Existing principles distinguish population, commercial formulation, product amount/duration, common topical treatment, no-add-on control, measurement, allocation/completion/analysis denominators, support and harms in the retained Meriva PASI record. - Related sources: S01 ## Evidence and sources ### S01 2015 · Report of a Meriva add-on trial for psoriasis PASI [PubMed](https://pubmed.ncbi.nlm.nih.gov/26090395/) Materials actually read: Stored summary read; external material unread Findings recorded in the summary: Both groups decreased, with a larger decrease in the Meriva add-on arm; exact adjusted CI unverified Record level: This is retained qualitative add-on-effect wording. Exact group/between-group estimates, intervals, denominators and adjustment remain unverified; it is not relabeled as monotherapy, replacement treatment or a new numerical result. Independent replication: One Meriva add-on report remains distinct from multiple endpoints, additional reports and independent trials. 63 assigned participants and 49 completers are original denominator records; unique-trial/participant totals, formulation-specific independent replication and endpoint-specific analysis denominators remain unverified. | Material | Public availability | Access status | Actually read | Notes | |---|---|---|---|---| | Stored existing trial summary | Existing stored summary acquired | Stored summary | Stored summary read | The stored report/citation summary was read. This does not record possession or abstract/full-text reading of the external original paper. Only the stored summary and bibliography were read. External papers, abstracts/full texts, registration, protocols, analysis plans, result tables and support disclosures remain unread. URLs and historical abstract narratives alone do not certify existence/public availability, accessibility, acquisition, reading, fulfilled conditions or independence. Each material date of 2026-09-08 is a retained historical evidence date. It is not an actual external-reading date and remains distinct from stored-material production on 2026-10-06 and actual completed content review. The actual completed-review date is unrecorded. | | External paper · Abstract/full text unread | Original bibliography link only; external content unread | Unread; no access attempt | Unread | The original PubMed URL and retained bibliography are linked. PMID/PMCID entries do not establish external identity, abstract/full-text acquisition, accessibility or reading. Only the stored summary and bibliography were read. External papers, abstracts/full texts, registration, protocols, analysis plans, result tables and support disclosures remain unread. URLs and historical abstract narratives alone do not certify existence/public availability, accessibility, acquisition, reading, fulfilled conditions or independence. Each material date of 2026-09-08 is a retained historical evidence date. It is not an actual external-reading date and remains distinct from stored-material production on 2026-10-06 and actual completed content review. The actual completed-review date is unrecorded. | | Trial registration and amendments | Needed material; existence and public availability unverified | Unread; no access attempt | Unread | Actual registration identifiers, contents, prespecification timing and amendments remain unverified. Prespecification is not certified. Only the stored summary and bibliography were read. External papers, abstracts/full texts, registration, protocols, analysis plans, result tables and support disclosures remain unread. URLs and historical abstract narratives alone do not certify existence/public availability, accessibility, acquisition, reading, fulfilled conditions or independence. Each material date of 2026-09-08 is a retained historical evidence date. It is not an actual external-reading date and remains distinct from stored-material production on 2026-10-06 and actual completed content review. The actual completed-review date is unrecorded. | | Study protocol | Needed material; existence and public availability unverified | Unread; no access attempt | Unread | Original study plans for interventions, comparators, endpoint hierarchy, timepoints and amendments remain unread. Only the stored summary and bibliography were read. External papers, abstracts/full texts, registration, protocols, analysis plans, result tables and support disclosures remain unread. URLs and historical abstract narratives alone do not certify existence/public availability, accessibility, acquisition, reading, fulfilled conditions or independence. Each material date of 2026-09-08 is a retained historical evidence date. It is not an actual external-reading date and remains distinct from stored-material production on 2026-10-06 and actual completed content review. The actual completed-review date is unrecorded. | | Statistical analysis plan | Needed material; existence and public availability unverified | Unread; no access attempt | Unread | Original analysis plans for between-group effects, multiplicity, adjustment and ITT/missing-data handling remain unread. Only the stored summary and bibliography were read. External papers, abstracts/full texts, registration, protocols, analysis plans, result tables and support disclosures remain unread. URLs and historical abstract narratives alone do not certify existence/public availability, accessibility, acquisition, reading, fulfilled conditions or independence. Each material date of 2026-09-08 is a retained historical evidence date. It is not an actual external-reading date and remains distinct from stored-material production on 2026-10-06 and actual completed content review. The actual completed-review date is unrecorded. | | Original funding, product-support, employee-authorship and COI disclosures | Needed material; existence and public availability unverified | Unread; no access attempt | Unread | Original funding, product provision, author employment, manufacturer roles and individual COI disclosures remain unread. Retained manufacturer-support wording is not relabeled as completed verification of each route. Only the stored summary and bibliography were read. External papers, abstracts/full texts, registration, protocols, analysis plans, result tables and support disclosures remain unread. URLs and historical abstract narratives alone do not certify existence/public availability, accessibility, acquisition, reading, fulfilled conditions or independence. Each material date of 2026-09-08 is a retained historical evidence date. It is not an actual external-reading date and remains distinct from stored-material production on 2026-10-06 and actual completed content review. The actual completed-review date is unrecorded. | ## Review criteria and methods These are Chamgap's own application conditions, informed by the relevant sections of official methodological guidance. They do not constitute official assessment-tool certification or a new efficacy score. - M03 [Cochrane Handbook 6.5 (2024), chapter updated 2023-08](https://www.cochrane.org/authors/handbooks-and-manuals/handbook/current/chapter-03) · §3.1, §3.2.1–3.2.3, MECIR C5/C7/C13 · Clearly record the question, eligibility conditions and reasons for changes, and distinguish variations in interventions. · Existing methodological links were reused for production. External originals were not reread and methodological content was not reassessed. - M04 [Cochrane Handbook 6.5.1 (2025), chapter updated 2025-03](https://www.cochrane.org/authors/handbooks-and-manuals/handbook/current/chapter-04) · §4.5, §4.6.1–4.6.3, MECIR C42 · Distinguish studies from reports and link them; do not omit a study solely because results are unreported. · Existing methodological links were reused for production. External originals were not reread and methodological content was not reassessed. - M08 [Cochrane Handbook 6.5 (2024), chapter updated 2019-10](https://www.cochrane.org/authors/handbooks-and-manuals/handbook/current/chapter-08) · §8.1–8.2.3, Table 8.2.a · Define the outcome and effect of interest, then examine randomization, deviations, missing data, measurement and selective reporting. · Existing methodological links were reused for production. External originals were not reread and methodological content was not reassessed. - M15 [Cochrane Handbook 6.5 (2024), chapter updated 2023-08](https://www.cochrane.org/authors/handbooks-and-manuals/handbook/current/chapter-15) · §15.2.4, §15.3.1–15.3.3 · Distinguish effect estimates, intervals, importance and applicability. Sample size alone does not determine precision. · Existing methodological links were reused for production. External originals were not reread and methodological content was not reassessed. - M19 [Cochrane Handbook 6.5 (2024), chapter updated 2019-10](https://www.cochrane.org/authors/handbooks-and-manuals/handbook/current/chapter-19) · §19.1.2, §19.2.1–19.2.4 · Harm questions may require different designs, populations and follow-up from efficacy questions. Case reports do not establish incidence rates. · Existing methodological links were reused for production. External originals were not reread and methodological content was not reassessed. ## What the statuses mean - Partly verified: Partial information from the stored summary is linked; detailed originals and content review remain incomplete. - Unverified: Required details cannot be established within the preserved scope. This does not establish absence of effects or studies, or safety. - Review incomplete: Review of existing content remains incomplete. - Met: This state is used only within the relevant conditions after material verification and content review. It was not automatically assigned in this work. - Not reported: Unreported within material actually read. Unread external material is not relabeled as unreported. - Inaccessible: This means actual access failure. External access was not attempted in this work, so this state was not assigned. - Not applicable: Used only with an application exception and reason based on the question scope. - Conflicting data: This requires actual comparison of materials; no new conflict judgment was made in this work. - Insufficient evidence for the conditions: This indicates gaps in additional material for the selected conditions. Unread material as a whole is not converted into an efficacy grade. ## Change history 2026-10-24 · Public page/materials 1.0. The public view and materials were prepared from the existing 33 items. No new clinical search, verification-state change or scoring was performed.